Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Ricardo Pereda"'
Autor:
Rafael Venegas, Albadio Pérez, Hugo Nodarse, Natacha Mezquia, Juan Carlos Rivero, Rodolfo Emilio Domínguez, Lissette del Rosario Lopez, Hubert Blas Rivero, Ricardo Pereda, Daniel Gonzalez, Julio Roberto Betancourt
Publikováno v:
Journal of Interferon & Cytokine Research
A previous report on 814 patients who were coronavirus disease 2019 (COVID-19) positive provided preliminary therapeutic efficacy evidence with interferon-α2b (IFN-α2b) in Cuba, from March 11 to April 14, 2020. This study re-evaluates the effective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8bb9e52ddafd6ab801cd70e083b83de3
Autor:
Rodolfo Emilio Domínguez, Natacha Mezquia, Lissette del Rosario Lopez, Rafael Venegas, Albadio Pérez, Hubert Blas Rivero, Juan Carlos Rivero, Daniel Gonzalez, Julio Roberto Betancourt, Ricardo Pereda
Publikováno v:
Journal of Interferon & Cytokine Research
A prospective observational study was conducted for assessing the therapeutic efficacy of interferon (IFN)-α2b in patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during the first month after the coronavirus diseas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8dde8ecb80354ad2cffa659f570ea6d
Autor:
Lissette del Rosario Lopez, Rafael Venegas, Albadio Pérez, Hubert Blas Rivero, Natacha Mezquia, Rodolfo Emilio Domínguez, Ricardo Pereda, Julio Raul Betancourt, Daniel Gonzalez, Juan Carlos Rivero
BackgroundEffective antiviral treatments are required to contain the ongoing coronavirus disease 2019 (COVID-19) pandemic. A previous report in 814 patients COVID-19 positive in Cuba provided preliminary therapeutic efficacy evidence with interferon-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::382265de6b1362131dac575d30f036e5
Autor:
Rodolfo Emilio Domínguez, Natacha Mezquia, Ricardo Pereda, Rafael Venegas, Albadio Pérez, Daniel Gonzalez, Julio Roberto Betancourt, Juan Carlos Rivero, Hubert Blas Rivero, Lizet del Rosario Lopez
BackgroundEffective therapies are needed to control the SARS-Cov-2 infection pandemic and reduce mortality associated with COVID-19. Several clinical studies have provided evidence for the antiviral effects of type I interferons (IFNs) in patients wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a43e8467450f34b81f0bdfce735282b0